Dalal Street faced intense macro pressure today, with the benchmarks closing deeply in the red at 23,824. However, the Indian healthcare space emerged as a massive silver lining.
The USFDA has officially approached Indian pharmaceutical majors to scale up production and address the severe shortage of the critical oncology drug, Ifosfamide. Tune into tonight's podcast to understand the structural impact of this export opportunity on top pharma stocks.
